Medgenics Share Discussion Threads

[237gmoney] 19/3/2013 13:35

Sicilian, The link below is for the webcast of the presentation which was held yesterday at the Roth Conference in CA. You might want to add this to the header.

It sounds like the company is in a strong position now with no debt and full program ahead. They also plan to expand into Europe next year with the Biopump and the FDA seem very positive about the discussions which have already taken place.

Also the company should be ready to release interim clinical data mid 2013 so that could be something to look forward to.

Webcast - Roth Conference Presentation - 18th March 2013 - 30mins long

[237gmoney] 18/3/2013 16:49

Not sure what the average trade is here on a good day but two fairly big trades gone through in the last few hours. 25k buy at the top end certainly a good sign.

From the placing on the 14th Feb the underwriters of the stock were granted a 45 day option to buy a further 840k shares and 420k warrants which should expire in the next few weeks. Not sure if the CKD results will be out before that deadline but hopefully those options will be taken up.

[237gmoney] 18/3/2013 12:14

Sicilian. Appreciate all your posts here and after some in depth research myself I have decided to buy in here today. Have spent a good few hours looking at this one and have read every post on this thread going back to day one and it really tells a story. This stock has had its ups and downs but introducing new technology into the pharma world takes time.

The new board members that have come in and the recent cash injection, certainly can only be positive for the company. If you read between the lines, the directors seem very positive about the companies future and hence thats why they raised cash the way they did. The Directors are not getting any younger and for some of them this is their last hurrah!

With the presentation at the Roth Conference this afternoon there should be more interest in this company in the coming weeks and with the CKD trial results due soon the company is about to enter an exciting time.

[supernumerary] 17/3/2013 21:12

I see Medgenics on the next AIM 100 exclusion list:

[sicilian_kan] 15/3/2013 08:32

The results at the SEC filing contain vastly more information and also blockbuster news.

There are lots of gems in the results issued yesterday which no news release or summary has picked up on. Most important to me is the following:

" In the interim we have commenced a phase IIa study of EPODURE in dialysis patients with ESRD in Israel as our first use of EPODURE in patients with complete renal failure, and a forerunner to the U.S. phase II study. To date, four patients have been enrolled and the preliminary results look comparable to our completed CKD study."

Read that again. You will see that they have slipped in at page 14 of the results that EPODURE is working to the same extent on dialysis patients as non-dialysis patients.

This is very, very important news as it will open up EPODURE to a new high revenue earning income stream. Remember the CKD results when reading this:

"The FDA issued a new guidance in 2011 indicating that hemoglobin should be maintained below 11 g/dl and high enough to avoid the need for increased transfusions, but not necessarily above 10 g/dl. In view of this new guidance, we note that the results of the completed study in 19 CKD patients showed that a single EPODURE administration elevated and maintained hemoglobin levels above 9 g/dl for at least three months in 14 of 19 patients, and for at least six months in nine of them, without need for any transfusions or EPO injections. The final study report of the CKD trial should be complete by end of the first quarter of 2013. With respect to our phase I/II study in ESRD patients, the initial early data obtained in the first three patients treated showed evidence of EPO secretion and early maintenance of hemoglobin levels."

Hmm, so only two more weeks to go before CKD final trial results too. Could be an interesting two weeks.

[andrbea] 14/3/2013 15:12

14 March 2013
Results out:

As of December 31, 2012, Medgenics had $6.43 million in cash and cash equivalents, compared with $5.00 million as of December 31, 2011. Net cash used in operating activities during the year was $8.61 million compared with $8.02 million used in 2011. During 2012 the Company received proceeds of $8.41 million from a private placement of common stock and warrants and $1.71 million from the exercise of options and warrants. In February 2013 Medgenics raised gross proceeds of $29.4 million in a public offering of common stock and warrants.

[supernumerary] 12/3/2013 15:15

Thanks for that. Worth updating the header?

[sicilian_kan] 12/3/2013 15:01

Good news today. They have just announced another very strong appointment to the BoD. Joseph J. Grano, Jr.'s background is:

- Former Chairman and CEO of UBS Financial Services Inc.

- Former Chairman of the Board of Governors of the National Association of Securities Dealers (which has been succeeded by the Financial Industry Regulatory Authority). FINRA oversees about 4,400 brokerage firms.

- Former Chairman of the Homeland Security Advisory Council, appointed by President George W Bush

- Former Director of National Sales, Merrill Lynch

Current market cap when fully diluted (assuming all warrants, options, underwriters allotments etc exercised) is $147m, with over $29m cash raised net in a placing last month.

[jammytass] 08/2/2013 17:23

sold down the river, the bod have filled there boots with shares at rock bottom prices in the years to come, also major shareholders have a free ride as well
with there give away prices, baxters have no more deals with this cmy and any tie inn deals are 5 years away the new ceo has made his mark ripped all small long term shareholders off. sell sell.sell

[sicilian_kan] 08/2/2013 08:04

I make it around 21m shares before with another 9.3m being added (fully diluted)

[sicilian_kan] 08/2/2013 07:57

I add that very fortunately, I am not holding. Might pick some up at £3.40-£3.50 though if they drop that low.

[pdt] 22/1/2013 07:14

Are we about to get some news? See the comments halfway through this article.



When some news of developments are announced I can see the price moving quickly.

[sicilian_kan] 09/1/2013 07:48

I hope so jammytass. The next updates (I expect all in this quarter) should be fundraising / a deal, further Phase I/IIa dialysis results and the start of Phase I/IIa trials in Infradure.

[jammytass] 09/1/2013 05:53

thanks for update ____ perhaps medu will update us now!!

[jammytass] 09/1/2013 05:53

thanks for update ____ perhaps medu will update us now!!

[sicilian_kan] 09/1/2013 00:34

Header updated.

[pdt] 15/12/2012 09:15

A good article on Infradure and it's potential.

[pdt] 29/11/2012 22:27

Up 5% at the close in the US. I wonder if that is on the back of the latest news release or the start of a more sustained run up. Be nice to see 800p.

[sicilian_kan] 29/11/2012 12:51

In summary, I think:

Positives
- The technology
- The directors and advisors
- The external approval

Negatives
- Fund raisings tend to be heavily dilutative and unnecessary warrants are issued
- I'm yet to be convinced as to how robust the IP protection in Europe is

[supernumerary] 29/11/2012 12:37

s_k - understood.

[sicilian_kan] 29/11/2012 10:31

supernumerary, yes I'm still around but very busy. One day I might update this very out of date header.

[gspanner] 27/11/2012 10:38

Been watching this for a while, interesting tech.

Managed to read the full abstract re: 'Medgenics Presents Preliminary Data from Phase IIa Study with EPODURE to Treat Anemia in Dialysis Patients at Kidney Week 2012'

reports results on only 1 patient.

Was somewhat difficult to find: had to look up author 'Berasenab' (from proof of concept study), and cross refernce with 'erythropeoitin' to find FRPO-259 abstract number...Was concerned since lack of numbers/data in RNS....

So just a note of caution. May be recruiting very well, but poster presentation seemed a little premature.

[pdt] 23/11/2012 12:52

I'm back in having done quite nicely on the last rise.

Getting the US patent granted should now enable them to do some development deals which should in turn have a positive impact on the price. Hopefully we may get some news soon in that area. As it reminded us in the News piece;

"Medgenics is focused on the development and manufacturing of its innovative Biopumps, aiming to bring them to market via strategic partnerships with major pharmaceutical and/or medical device companies."